Клинические исследования
Cancer clinical trials, explained.
One page for each Phase 1 and Phase 2 cancer study we track: the drug, how the study runs, the papers behind it, and the people running it. Pick a cancer to start.
216 studies · 17 cancers · recruiting now
216 Phase 1 · 690 Фаза 2
Open the Phase 2 page · a list of only those studies
Registry status checked
Triangle is made by Triangle Health, Inc.
How these trials work
What is a Phase 1 cancer trial?Common questions
Educational notes, not clinical evidence.
By cancer
- Brain and CNS39 studies
- Breast9 studies
- Lung and thoracic25 studies
- Prostate3 studies
- Leukemia, lymphoma, and myeloma83 studies
- Pancreas5 studies
- Colorectal and anal5 studies
- Liver and bile duct10 studies
- Stomach and esophagus5 studies
- Ovary and gynecologic8 studies
- Kidney and bladder5 studies
- Melanoma and skin6 studies
- Head and neck3 studies
- Thyroid and neuroendocrine4 studies
- Sarcoma3 studies
- Neuroblastoma and other childhood tumors2 studies
- Solid tumors and other cancers1 study
Recent films
Start with a drug.
Short explainers built from the registry record. Each one sits on the trial page with the papers and the people.
All studies
Brain and CNS
- Autologous total tumor mRNA
- TGX-007
- Chimeric Antigen Receptor T-Cell Therapy
- IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated
- Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed
- Tarlatamab + Radiation Therapy
- 15.GPC3-CAR T cells
- Laser Interstitial Thermal Therapy + Lomustine
- Oncolytic Adenovirus Ad5-DNX-2401
- EGFR Inhibitor ERAS-801
- Neural Stem Cells-expressing CRAd-S-pk7
- Cord Blood-derived Expanded Allogeneic Natural Killer Cells
- G207
- B7-H3.CD28Z.CART
- NK Cells
- PEPIDH1M vaccine + vorasidenib
- HEGFRvIII-CD3 (BRiTE)
- C7R-GD2.CART cells (IV and ICV infusion)
- ASTX727 for IDH-Mutant Glioma
- LUTATHERA (Lutetium Lu 177 dotatate)
- CARv3-TEAM-E T cells
- STARLITE
- Sitagliptin
- Ad-hCMV-Flt3L
- Topotecan
- 177Lu-PSMA-617
- Bevacizumab
- Anti-GARP Chimeric Antigen Receptor-T Cells
- Personalized neoantigen DNA vaccine
- SCRI-CARB7H3(s); B7H3-specific chimeric antigen receptor (CAR) T cel
- ADV/HSV-tk (gene therapy)
- DB107-RRV
- CUE-102
- SC-CAR.GPC3xIL15.21 CAR T cells
- GD2 CAR T cells
- M032 Oncolytic Virus + Pembrolizumab
- Ibrutinib + Indoximod
- Ad5-yCD/mutTKSR39rep-ADP adenovirus
- SIACI of cetuximab and bevacizumab
Lung and thoracic
- TNhYP218 CAR T Cells
- Honokiol
- Neoadjuvant Durvalumab + Tremelimumab ± Chemotherapy
- Navlimetostat + Pumitamig
- Tepotinib + Ivonescimab
- Tumor-infiltrating Lymphocytes (TIL)
- SX-682 + Proton Craniospinal Irradiation
- Response-Adapted PULSAR Radiotherapy
- Valemetostat
- Locally manufactured adoptive cellular therapy (ACT) product
- Peptide vaccine
- Dupilumab
- N-803 + Nivolumab and Ipilimumab
- Papaverine
- Gilteritinib
- Pembrolizumab + Single-Agent Chemotherapy
- GC511B CAR-T Cell
- Ivonescimab + Chemotherapy and Radiosurgery
- Alectinib ± Upfront Radiosurgery
- Locally manufactured adoptive cellular therapy (ACT) product
- MRX-2843 + Osimertinib
- [18F]-αvβ6-BP
- Adenosine A2B Receptor Antagonist PBF-1129
- Ladarixin + Sotorasib
- Pembrolizumab + Chemotherapy and Image-Guided Surgery
Leukemia, lymphoma, and myeloma
- ViPOR Combination
- CD19/CD22-CAR-transduced T cells
- PMD-026 (RSK1 Inhibitor)
- CD22CART cell
- Danvatirsen
- NT-I7 after cilta-cel for multiple myeloma
- Pomalidomide after CAR T for B-cell leukemia or lymphoma
- Selinexor Maintenance After CAR T
- CD79b-19 CAR T cells
- Decitabine + Venetoclax Maintenance After Transplant
- CD371-specific/YSNVz/I-18 CAR T cells
- Ziftomenib Maintenance After Transplant
- NY-ESO-1 TCR/IL-15 Cord Blood NK Cells
- CAR T Cells
- NT-I7 after CAR T for large B-cell lymphoma
- Epcoritamab
- Ruxolitinib + Venetoclax
- CRD3874-SI (STING Agonist)
- Zanubrutinib + Tafasitamab
- Venetoclax
- CLAG-M or FLAG-Ida + Total Body Irradiation Before Transplant
- Tafasitamab
- CAR.70 / IL-15 / TGFBR2-Knockout Cord Blood NK Cells
- miRisten (miR-126 Inhibitor)
- High-Dose Ascorbate + Azacitidine and Venetoclax
- CIML NK cells with venetoclax for AML
- Axatilimab ± Azacitidine
- MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
- Eganelisib + Venetoclax and Azacitidine (GAVEL)
- Epcoritamab + Ibrutinib
- Pomalidomide with DA-EPOCH for HIV-associated lymphoma
- TCR alpha beta / CD19+ depleted haploidentical hematopoietic
- Autologous CD5.CAR/28zeta CAR T cells
- BCMA-TGFβ CAR-T cells (0.50 x 10^6 cells/kg)
- Loncastuximab Tesirine + Rituximab After Radiosurgery
- CAR.70/IL15-transduced CB-NK cells
- FOLR1 CAR T-cells
- Durvalumab
- Inotuzumab Ozogamicin
- Pemigatinib After Chemotherapy
- CD19x22 CAR T Cells
- WS-CART-CS1
- Mosunetuzumab + Chemotherapy
- Emapalumab for GVHD Prevention After Transplant
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
- Cyclosporine
- CIML NK
- Cytokine Induced Memory-like Natural Killer Cells
- SL-401
- PK-Directed Melphalan Before Autologous Transplant
- Ruxolitinib + CHOP
- Sirolimus
- CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes
- Anti-CD19/CD20/CD22 CAR T-Cells
- CD123-CAR T
- Decitabine + FLAG-Ida and Total-Body Irradiation
- Zanubrutinib + Pola-R-CHP and High-Dose Methotrexate
- Pralatrexate + Bendamustine and TBI Before Donor Transplant
- DC/MM Fusion Vaccine
- Iomab-B Followed by CAR-T Cell Therapy
- DC/AML Fusion Vaccine
- RhDNase I
- Venetoclax Plus CLAG-M
- Mezigdomide + Talquetamab (MAGENTA)
- CART
- ATRA With Carfilzomib
- CD30 Bispecific Antibody-Armed T Cells
- EAGD T-cell
- Revumenib + 7+3 Induction and Midostaurin
- Tazemetostat for Relapsed/Refractory AML
- Acalabrutinib Maintenance After Cellular Therapy
- ADCLEC.syn1 CAR T cells
- FHD-286
- EBV-Specific T Cells (GRALE)
- CC-99282 + Rituximab
- CPX-351 + Gemtuzumab Ozogamicin
- Tegavivint
- CIML-NK Cells
- 8/12-Day Production of Car-T Cells
- Roginolisib + Venetoclax and Rituximab
- Talquetamab
- CD19x22 CAR T
- CD19.CAR T Cells
Liver and bile duct
- CAR-T cell
- Nivolumab, Fluorouracil, and Interferon Alpha 2B
- CARE T cells
- Sorafenib, Bevacizumab and Atezolizumab
- Ipilimumab and Nivolumab
- Emavusertib + Gemcitabine, Cisplatin and Durvalumab
- SBRT + atezolizumab and bevacizumab
- Atezolizumab + Bevacizumab + SBRT
- Chemoimmunotherapy + Spatially Fractionated RT and Deep Hyperthermia
- DNAJB1-PRKACA peptide vaccine
Triangle






